BAL PHARMA LTD.
BALPHARMA · General/Diversified · NSE
₹90
Current Market Price
Fair Value (DCF)
₹107
Discount to FV
+19.1%
Updated just now
YieldIQ Score
55/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
21%
ROE
7.6%
Debt/Equity
1.94
WACC
11.1%
Market Cap
₹142.49 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.0%
Return on capital employed
EV / EBITDA
11.9×
Enterprise multiple
Debt / EBITDA
6.6×
Leverage vs earnings
Interest Coverage
1.4×
EBIT covers interest
Current Ratio
1.07×
Short-term liquidity
Asset Turnover
0.93×
Revenue per ₹ of assets
Revenue CAGR (3Y)
1.1%
3-year revenue growth
Revenue CAGR (5Y)
4.6%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹89.5
Bear case
Margin of Safety -61.0%
Implied upside -37.9%
Base case
Margin of Safety +13.8%
Implied upside +16.0%
Bull case
Margin of Safety +23.1%
Implied upside +30.0%
Ratio Trends
BALPHARMA · last 8 annual periods
ROE
7.6%
ROCE
14.0%
Operating Margin
—
Debt / Equity
1.94×
PE
41.5×
EV / EBITDA
9.8×
Historical Financials
BALPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹280 Cr | ₹302 Cr | ₹339 Cr | ₹303 Cr | ₹312 Cr | +2.7% |
| EBITDA | ₹27.1 Cr | ₹24.4 Cr | ₹33.6 Cr | ₹31.8 Cr | ₹33.8 Cr | +5.7% |
| EBIT | ₹19.6 Cr | ₹16.9 Cr | ₹24.3 Cr | — | — | +5.5% |
| PAT | ₹5.6 Cr | ₹2.6 Cr | ₹7.4 Cr | ₹7.2 Cr | ₹6.3 Cr | +2.9% |
| EPS (diluted) | ₹3.71 | ₹1.68 | ₹4.96 | — | — | +7.5% |
| CFO | ₹26.8 Cr | ₹-1.5 Cr | ₹22.8 Cr | ₹20.3 Cr | ₹30.4 Cr | +3.2% |
| CapEx | ₹-8.5 Cr | ₹-14.6 Cr | ₹-11.0 Cr | ₹-18.8 Cr | ₹-22.4 Cr | — |
| FCF | ₹18.3 Cr | ₹-16.2 Cr | ₹11.8 Cr | ₹1.5 Cr | ₹8.1 Cr | -18.6% |
| Total Assets | ₹261 Cr | ₹313 Cr | ₹320 Cr | ₹336 Cr | ₹376 Cr | +9.6% |
| Total Debt | ₹107 Cr | ₹133 Cr | ₹142 Cr | ₹150 Cr | ₹160 Cr | +10.6% |
| Shareholders' Equity | ₹58.6 Cr | ₹63.8 Cr | ₹72.0 Cr | ₹77.4 Cr | ₹82.2 Cr | +8.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BALPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
KREBSBIO KREBSBIO | — | — | Pending | 10.4% | — |
ALPA ALPA | — | — | Pending | 8.1% | — |
NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.3% | — |
PAR PAR | — | — | Pending | 13.5% | — |
BROOKS BROOKS | — | — | Pending | 20.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
9 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹5.40/sh
Last payout
2025-09-18
₹1.20
Peak payout
₹1.20
Trailing yield
1.34%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. BAL PHARMA LTD. (BALPHARMA.NS) trades at 89.50 vs a model fair value of 106.60, a gap of 19.1%. Piotroski F-score: 6/9. Moat label: Narro...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BALPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BALPHARMA →
Compare
Head-to-head with peers
Compare BALPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BALPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.